BioPharmSignal logoBioPharmSignal

Biotech News

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Protara Therapeutics (TARA)Protara TherapeuticsCompany update

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat

Open original release

Related news

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

KURAKura Oncology2026-05-19 20:02 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

BMYBMYBristol-Myers Squibb Company2026-05-21 21:01 EST

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

GSKGSK plc2026-07-21 10:28 EST

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

ELVNEnliven Therapeutics2026-05-21 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

View all latest news

Protara Therapeutics

Protara Therapeutics is a biotechnology company focused on rare disease and oncology programs, including metabolic and lymphatic disease. Its story centers on high-unmet-need conditions and a narrow pipeline.

Recent company news

TARAProtara Therapeutics2026-05-20 12:00 EST

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-04-27 20:05 EST

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

Stock data

Close
4.04 USD
Market cap
243.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States